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Abstract The purpose of this paper is to serve as a reference
to aid in the management of this poorly understood intracra-
nial malignancy. The authors report their experience treating
the eighth ostensible case of a primary intracranial alveolar
soft part sarcoma (ASPS). A 21-year-old man presented to
hospital after collapsing. He gave a 1-year history of head-
ache, a 2-month history of reduced visual acuity and on ex-
amination had left facial paraesthesia with left-sided incoordi-
nation. MRI of the brain revealed a large left posterior fossa
mass. The patient underwent resection of the tumour with
good recovery in function. Immunohistochemical analysis of
the tumour specimen confirmed an ASPS, and multimodal
imaging in search of an extra-cranial disease primary was
negative. A review of the literature yielded only seven other
cases of primary intracranial ASPS. A variety of diagnostic
imaging modalities were employed in search of a disease pri-
mary, as were various combinations of surgical resection, che-
motherapy and radiotherapy as treatment. Half of the cases
documented delayed disease recurrence. The authors discuss
t h e f o l l ow i n g : t h e u n i q u e r a d i o l o g i c a l a n d
immunohistological characteristics of this disease including
the potential for its misdiagnosis; the investigations required
to diagnose a primary intracranial ASPS; the efficacy of
current medical and surgical treatment options and the factors
that will aid in prognostication. This is the first review of this
new primary intracranial malignancy. From our analysis, we
offer a joint radiological and immunohistochemical algorithm
for the diagnosis of primary intracranial ASPS and specific
operative considerations prior to resection.
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Introduction
Alveolar soft part sarcoma (ASPS) is an extremely rare
malignancy of unknown cellular origin accounting for 1%
of all soft tissue sarcomas. ASPS effects a younger patient
population with a peak incidence between 15 and 35 years
[9]. The primary site for ASPS is most commonly the
trunk or extremities, but it can also arise from the abdo-
men or the head and neck. Beyond its rarity, ASPS is also
unusual in its characteristics of metastasis. Other high-
grade soft tissue sarcomas rarely metastasize to the brain,
whereas ASPS has a high metastatic potential and will
involve the brain in up to 19% of cases [19]. To date,
there are only ten cases of ASPS presenting with neuro-
logical symptoms, four of which had concomitant lung
metastasis [4].
Here, we present the eighth ostensible case of primary in-
tracranial ASPS and the second case of ASPS arising in the
posterior fossa [1]. In conjunction with a review of the litera-
ture, we discuss the diagnosis, evidence for medical and sur-
gical management, factors aiding in prognostication and sur-
gical considerations for this new primary intracranial malig-
nancy. Our aim is to provide a comprehensive reference for
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any clinicians who encounter this incompletely understood
disease entity in the future.
Case
History and examination
A 21-year-old man presented to his local hospital after col-
lapsing at home due to leg weakness. He gave a 1-year history
of persistent headache accompanied by a 2-month history of
blurred vision, reduced sensation on the left side of his face
and occasional difficulty in walking. He had a history of learn-
ing difficulties and anxiety with no other medical problems.
On admission, he was fully conscious with a Glasgow Coma
Score of 15/15. Cranial nerve examination revealed a left 4th
and 6th nerve palsy causing diplopia and reduced sensation in
all distributions of the left trigeminal nerve. There was left-
sided nystagmus in conjunction with left cerebellar signs caus-
ing a broad-based gait. Fundoscopy revealed papilloedema.
Peripheral neurological examination was unremarkable.
Investigations
MRI brain with contrast revealed a broad-based and extra-
axial mass measuring 4 × 4 × 5 cm in the left posterior fossa.
It was isointense to grey matter on T1-weighted imaging (WI)
and heterogeneous on T2WI imaging with avid heterogeneous
T1WI enhancement post-gadolinium administration.
Diffusion-weighted imaging showed no restriction with some
small cystic components. Evidence of mass effect was noted
on the left cerebellar lobe and the midbrain with evidence of
hydrocephalus. Multiple small vessels were intimately associ-
ated with the lesion. An initial radiological diagnosis of me-
ningioma was made (Fig. 1).
Audiometry showed a left sensironeural hearing loss
>70 db in the left ear, and ophthalmology review confirmed
bilateral papilloedemawith 6/9 acuity in the right eye and 6/18
acuity in the left eye.
Operation
The patient was positioned left side up in the park bench
position with the head pinned. A left occipital external ven-
tricular drain was placed to release cerebrospinal fluid under
high pressure. Following this, a left suboccipital and
retromastoid craniotomywas performed exposing the margins
of the transverse and sigmoid sinuses. The dura was noted to
be full after the bone flap was removed, and the cerebellum
was tense and bulging after dural opening. Extra-axial tumour
was encountered at 2 cm depth. The tumour was encapsulated
but with no clear plane for dissection from the cerebellum and
highly vascular. No definite site of attachment to the dura or
brain was found.Microsurgical dissectionwas performedwith
neuro-physiological monitoring ensuring preservation of the
5th, 7th and lower cranial nerves. During dissection, severe
bleeding was encountered, especially venous, which necessi-
tated 13 units of packed red cell transfusion. The haemorrhage
was only fully controlled after total microsurgical resection.
The dura was then closed with bone flap replacement, and the
patient transferred to intensive care.
Pathology
Macroscopic analysis showed a mixed cream and brown rub-
bery tissue. Microscopic appearances showed distinct nests of
medium to large plump epithelioid cells with prominent nuclei
and a granular eosinophilic cytoplasm. The nests were
intersected by numerous fine vessels and showed no evidence
of necrosis. Staining revealed moderate numbers of cells with
granular to needle-shaped cytoplasmic inclusions that were
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Fig. 1 Pre-operative axial T2
pre-contrast (left) and T1 post-
contrast (right) showing a large
broad-based extra-axial mass
measuring 4 × 4 × 5 cm in the left
posterior fossa effacing and
displacing the fourth ventricle
PAS positive and diastase-resistant. Immunocytochemistry
was diffusely positive for myo-D1 with nuclear positivity for
INI1. Stains for desmin, CK-MNF, Cam 5.2, chromogranin,
synaptophysin, s100, EMA, smooth muscle actin, CD117,
PLAP, CD30, GFAP, beta-hCG, AFP, hepar-1 and RCC were
all negative. Given that a broad differential had been excluded,
transcription factor E3 (TFE3) staining was performed and
showed strong nuclear positivity confirming an alveolar soft
part sarcoma.
Post-operative course
Immediately post-operation, the patient had worsening of his
cranial nerve dysfunction with a new left facial weakness.
During the next few weeks, his cranial nerve palsies gradually
improved, and he was eventually able to ambulate indepen-
dently. At this point, he was referred to the oncology team for
further investigation.
Extensive imaging in search of a primary lesion site was all
negative, including repeat whole-body FDG-PETscans over a
2-month period. At 10-month follow-up, he is living at home
requiring no formal package of care. He is currently receiving
regular follow-up as part of surveillance by his oncology team.
A repeatMRI brain at this time showed no evidence of disease
recurrence, and CT of the chest, abdomen and pelvis showed
no disease primary (Fig. 2).
Primary intracranial alveolar soft part sarcoma
It is known that ASPS has an unusual predilection for intra-
cranial metastasis in comparison to other soft tissue sarcomas.
It is reported that intracranial metastatic ASPS is only ob-
served with concomitant extra-cranial metastatic disease and
never in the absence of lung metastases [11, 20]. Given it is
estimated that the accuracy of FDG-PET in unknown primary
tumour detection has a sensitivity of 87% and specificity of
71% [8] and our patient exhibited no radiological evidence of
metastatic lung disease, we posit that this is the eighth osten-
sible case of primary intracranial ASPS reported in the English
literature.
An online search of the English literature for the terms
Balveolar soft part sarcoma^ and Bprimary^ yielded 126 re-
sults. One hundred twenty-three of these were discarded as
they did not pertain to intracranial disease. Review of refer-
ences for the remaining three cases provided four further rel-
evant cases giving a total of seven reports of primary intracra-
nial ASPS [13] [22] (Table 1).
In the eight cases of primary intracranial ASPS, a younger
patient population is effected as would be expected.
Furthermore, the age-related gender ratio inversion described
by Ordonez is preserved in primary intracranial ASPS; the
youngest cases being female and the older cases being male
[17]. Presentation is usually due to symptoms of raised intra-
cranial pressure or seizure with two cases presenting as a large
frontal forehead mass.
Diagnosis
An initial radiological diagnosis of meningioma was made in
our case similarly to four of the other cases of primary intra-
cranial ASPS. Typically, meningiomas are isointense to
hypointense in comparison to grey matter on T1WI MRI with
variable signal intensity on T2WI [19]. ASPS is most com-
monly known to be isointense to hyperintense on T1WI and
characteristically hyperintense on T2WI, but this is in com-
parison to muscle [10].
As of the time of writing, there is no literature specifically
addressing the MRI characteristics of ASPS with regards to
T1 and T2WI when compared to grey matter. This is presum-
ably because of the extreme rarity of the disease arising as a
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Fig. 2 Post-operative axial T2
(left) and T1 MRI (right) brain
post-contrast at 9 months post-
resection. Evidence of associated
gliosis with some haemosiderin
deposit in the left cerebellar
hemisphere. No pathological
enhancement is seen in the area of
the resection cavity to indicate
tumour recurrence
primary intracranial tumour and therefore the radiological di-
agnosis being made upon detection of the soft tissue primary
and its characteristics relative to muscle.
Retrospective review of the MRI characteristics of our pa-
tient showed that the tumour satisfied criteria for a benign
posterior fossa tumour, such as a meningioma, but also for
those of ASPS when compared to muscle. Of the seven other
cases of primary ASPS, five documented MRI characteristics,
where the tumours were all described as either hypo- to
isointense on T1WI and markedly hyperintense on T2WI
when compared to grey matter. Similarly, all lesions showed
avid and heterogeneous enhancement on T1WI following
contrast administration. Specific comment was made to the
presence of flow voids within the tumour on T2WI in two
cases; a characteristic noted in all 19 patients who underwent
MRI in an oncological trial for treatment of extra-cranial
ASPS [15]. Given this, primary ASPS may mimic meningio-
ma on initial radiological investigation, with a differential di-
agnosis including hemangiopericytoma and medulloblastoma
when encountered in the posterior fossa.
Macroscopically, ASPS is typically a round or lobulated
soft mass of a yellow-white color [16]. The histological diag-
nosis of ASPS is based upon its alveolar growth pattern and
unique cytological features such as diastase-resistant periodic
acid-Schiff (PAS-D) crystalline cytoplasmic inclusion bodies
[4]. It is this characteristic histological appearance that has led
to the nomenclature Balveolar soft part sarcoma^ as it is com-
parable, although unrelated, to the alveoli of the lungs.
Histological examination in our case did show PAS-D cyto-
plasmic positivity, but it is possible for ASPS tumours lacking
these characteristic features to be mistaken for a wide differ-
ential of malignancies. This occurred in case 3 where a pre-
operative histological diagnosis of meningioma was made fol-
lowing biopsy. The histological differential of ASPS includes
the following: renal cell carcinoma (RCC); adrenocortical car-
cinoma (ACC); hepatocellular carcinoma (HCC); paediatric
age RCC; malignant melanoma; paraganglioma; alveolar
rhabdomyosarcoma; rhabdoid meningioma; perivascular epi-
thelioid cell tumours (PEComas) and granular cell tumours.
Given this broad differential, to confirm the diagnosis of
ASPS, several specific immunohistochemical markers must
be used to differentiate these separate malignancies. RCC
can be excluded fromASPS as it shows a unique RCCmarker
protein. ACC will show immunoreactivity to synaptophysin,
HCC will be positive for hepar-1 and rare paediatric RCCs are
positive for CK. Similarly, alveolar rhabdomyosarcoma will
show positivity for desmin, PEComas for smoothmuscle actin
and rhabdoid meningiomas will show eosinophilic inclusions
strongly positive for EMA. Malignant melanoma,
paraganglioma and granular cell tumours all stain positive
for the S-100 protein (Fig. 3).
At times, the characteristic cytostructure that aids in the
identification of ASPS can be absent. When this occurs,Ta
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immunohistochemical testing for the nuclear transcription fac-
tor E3 (TFE3) fusion gene can be employed. Recently, an
antibody directed against the C-terminus of the TFE3 fusion
gene has proven a highly sensitive and specific marker for
ASPS. Despite this, caution must be exercised as the TFE3
gene is also present, but in a different configuration, in paedi-
atric RCC and also in granular cell tumours [2]. Therefore, to
fully confirm the diagnosis of a primary intracranial ASPS,
not only must the nuclear TFE3 fusion gene be detected, but
other histological differentials must be excluded via specific
molecular testing as well as the potential for any renal mass on
imaging [15].
The cellular origin of ASPS remains an issue of debate and
therefore makes investigation for the origin of primary disease
difficult. Originally, it was thought that ASPS was a variant of
granular cell tumour, but more recent immunohistochemical
studies point towards a muscular origin [6]. Given the cellular
origin of the ASPS remains ambiguous, there is no defined ra-
diological protocol for the detection of primary disease.
Excluding case 5 where details are not given, all patients had
radiological imaging of the chest and abdomen, but the imaging
modalities employed varied widely. CT of the chest, abdomen
and pelvis was used in three cases to search for a primary; with
CT of the chest alone in two further cases. Ultrasonography and
bone marrow biopsy were used in four cases and whole-body
PET in four cases. In case 2, a Bbone scan^was performed but no
further details of the exact imaging techniques used were given.
FDG-PETscanning may be the most useful imaging modality in
the search of an ASPS primary, with an estimated sensitivity of
93.7% in the detection of soft tissue sarcomas [14]. Therefore, to
confirm a primary intracranial ASPS, an initial investigation for
primary disease warrants detailed imaging of the chest to exclude
pulmonary metastases and also whole-body FDG-PET in search
of disease primary.
Treatment
Chemotherapy, radiotherapy and surgical resection have been
employed individually and in combination in the management
of primary ASPS. Given the rarity of the disease, reports into
the outcomes of these treatment modalities are limited to large
case series and do not address ASPS effecting one specific
anatomical region.
Surgery may be considered the first-line treatment in local-
ized ASPS and may potentially increase long-term survival
[22]. Prognostic factors that may guide the surgeon in counsel-
ing patients include: pre-operative Karnofsky Performance
Score (KPS), tumour size, extent of surgical resection possible
and patient age. A pre-surgical KPS of 70 and above has been
reported as a good prognostic indicator associated with a
higher median survival in those with metastatic sarcoma of
the brain [3]. Primary tumour size is also thought to influence
long-term survival [23]. In a series of 20 children and young
adults with ASPS, progression-free survival was significantly
reduced in those with a primary tumour greater than 5 cm in
size [11]. Here, patients were treated with a combination of
surgical resection, chemotherapy and radiotherapy dependent
upon the extent of metastatic disease. Contrary to this, a more
recent case series of 11 patients treated surgically concluded
that neither tumour size, location nor interval between diag-
nosis and treatment effected outcome [7]. It is of note however
in this series, all patients underwent total surgical excision and
adjuvant radiotherapy with the authors conceding their num-
ber of cases being too small to perform meaningful analysis.
A favorable outcome from complete microscopic resection of
localizedASPS has been reported from several series. A study by
the Italian Soft-Tissue Sarcoma Cooperative Group found that
100% of patients who underwent total surgical resection of lo-
calized ASPS showed no evidence of disease at follow-up rang-
ing from 11 to 243 months, often with surgery being the only
treatment modality employed [5]. Similar outcomes have been
confirmed in the paediatric and young adult population following
total surgical resection of primary disease [11, 18]. Increased age
at diagnosis has been shown to have an association with worse
prognosis, but this correlation may be due to younger patients
presenting with more localized disease when compared to those
aged 17 years and above [11, 12]. Disease-free and overall sur-
vival rates in those with localized ASPS have been reported at 71
and 88% at 5 years, respectively [20].
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Fig. 3 Left—Cells arranged in
alveolar pattern with abundant
granular cytoplasm (hematoxylin
and eosin, ×100). Right—Positive
nuclear uptake for TFE3 gene
(TFE3, ×100)
In our review of primary intracranial ASPS, total surgical
resection was achieved in six of eight cases. Total surgical
resection was deemed unsafe in two cases due to difficult to
control large-volume haemorrhage. Three out of the seven
cases were detailed experienced localized disease recurrence,
with two of these patients having undergone total surgical
resection and the other subtotal resection. In two instances,
patients received adjuvant chemo- and radiotherapy and in
the other radiotherapy alone. Of the four patients who remain
disease-free, two underwent total surgical resection alone, one
underwent total surgical resection plus adjuvant chemothera-
py and one total surgical resection plus radiotherapy.
It is of note that in the three instances of disease recurrence,
the follow-up time is significantly longer than in those who
remain disease-free. Also, contrary to the association between
younger age at presentation and favorable prognosis reported
from extra-cranial primary ASPS, the only three patients un-
der 17 years of age in this reviewwere the ones to demonstrate
disease recurrence.
ASPS appears to be a chemotherapy-insensitive pathol-
ogy. Eleven patients with both localized and metastatic
ASPS who received chemotherapy failed to show any re-
sponse to treatment. Chemotherapeutic agents used were
varied including antimetabolites, alkylating agents, mitotic
inhibitors, anthracyclines, antimicrobial agents, antineo-
plastics, antifolates, COX-2 inhibitors, interleukin-2,
interferon-alpha and TNP-470 [11]. The largest report of
results from chemotherapeutic treatment in ASPS showed
only 3% of patients responded to doxorubicin-based ther-
apy. It is of note that total number of patients was low at 29
but did include patients with both localized and metastatic
ASPS. The majority of patients treated with chemotherapy
developed disease progression, and no partial or minor
responses were seen [20].
The role of radiotherapy in the treatment of ASPS re-
mains unknown. The few case series documenting the re-
sponse to radiotherapy are unable to demonstrate any clin-
ical benefit due to small study numbers [11, 20].
Radiotherapy has been employed in an adjuvant and palli-
ative fashion. In those patients where adjuvant radiothera-
py was used, the decision to do so was based upon the
perceived high risk of recurrence for their tumours.
Clinico-pathological factors used for this assessment were
microscopically positive surgical margins, anatomic loca-
tion, presentation with a recurrent primary site and tumour
size. A study of 18 patients focusing on the role of radio-
therapy in ASPS concluded that it may be of use in the
prolonged local control of disease after limited surgical
resection and also provide meaningful palliation in meta-
static ASPS [21].
As the long-term prognosis for localized ASPS is favor-
able, patients will require extended periods of follow-up with
appropriate cranial imaging. Cases 3 and 4 highlight the need
for extended follow-up as disease recurrence can occur in a
delayed fashion. Also, extended follow-up is recommended to
ensure that no initially occult primary disease focus renders
itself detectable. Furthermore, even in patients with wide-
spread metastatic disease, there exists an unexplained subset
of long-term survivors beyond 5 years from initial treatment.
These patients highlight both the potential indolent nature of
evenmetastatic ASPS and our incomplete understanding of its
natural history. In time, molecular analysis of these patient
subsets may provide an explanation for this variation in
survival.
Clinical implications
Based upon the clinical features of the reported cases of pri-
mary intracranial ASPS in conjunction with literature to date,
there are several implications for consideration in the manage-
ment of this disease. First, our case gives further evidence that
ASPS may arise as a primary intracranial malignancy within
the posterior fossa. Second, to confidently demonstrate a pri-
mary intracranial ASPS, whole-body FDG-PET scanning
must be performed to exclude a soft tissue primary as well
as CT imaging of the thorax to rule out pulmonary involve-
ment. If unable to test for the TFE3 fusion gene, then imaging
of the kidneys should also be performed to exclude a renal
mass. Third, primary intracranial ASPS should be borne in the
mind of the neurosurgeon when confronted with what radio-
logically appears to be an atypical meningioma,
haemangiopericytoma or medullablastoma in the younger pa-
tient. Fourth, total surgical resection of primary disease is the
main treatment option as neither chemotherapy nor radiother-
apy has proven benefit in curative management in extra-
cranial disease. Furthermore, where the benefit of a diagnostic
biopsy is available prior to resection, pre-operative prepara-
tion for large-volume haemorrhage is advised. Fifth, contrary
to the trend in extra-cranial primary ASPS, younger patients
with primary intracranial ASPS may have a worse prognosis.
Conclusions
At this moment, we know neither the natural history nor the
cellular origin of this primary intracranial malignancy. Our
case makes part of this review which is the most comprehen-
sive to date of this disease. Still, we cannot strongly conclude
what may be the best treatment options for primary intracra-
nial ASPS from these few cases, despite significant literature
documenting experience with extra-cranial disease. We there-
fore encourage other clinicians to report their encounters with
this new primary intracranial malignancy in the endeavor to
create a greater understanding of this disease and its best
management.
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